Dimension Therapeutics Company Profile (NASDAQ:DMTX)

About Dimension Therapeutics (NASDAQ:DMTX)

Dimension Therapeutics logoDimension Therapeutics, Inc. is a gene therapy company. The Company is focused on discovering and developing therapeutic products for people living with rare diseases associated with the liver and caused by genetic mutations. It has programs for hemophilia B, hemophilia A, ornithine transcarbamylase (OTC) deficiency, and glycogen storage disease type Ia (GSDIa). The Company's gene therapy product candidates and programs are designed to provide a functional copy of an abnormal or missing gene using the advanced adeno-associated virus (AAV)-based vector delivery technology. DTX101 is the Company's lead gene therapy product candidate designed to deliver Factor IX (FIX), gene expression in patients with hemophilia B. DTX201 is its Factor VIII (FVIII) gene therapy program for the treatment of hemophilia A. DTX301 is its gene therapy product candidate designed for the treatment of patients with OTC deficiency. DTX401 is its gene therapy program for the treatment of patients with GSDIa.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NASDAQ:DMTX
  • CUSIP: N/A
  • Web: www.dimensiontx.com
Capitalization:
  • Market Cap: $151.26 million
  • Outstanding Shares: 25,052,000
Average Prices:
  • 50 Day Moving Avg: $5.20
  • 200 Day Moving Avg: $2.35
  • 52 Week Range: $1.05 - $7.42
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -3.98
  • P/E Growth: 0.000
Sales & Book Value:
  • Annual Revenue: $14.88 million
  • Price / Sales: 10.06
  • Book Value: $1.44 per share
  • Price / Book: 4.15
Profitability:
  • EBITDA: ($50,870,000.00)
  • Net Margins: -358.21%
  • Return on Equity: -98.72%
  • Return on Assets: -61.95%
Debt:
  • Debt-to-Equity Ratio: 0.09%
  • Current Ratio: 3.33%
  • Quick Ratio: 3.33%
Misc:
  • Average Volume: 212,092 shs.
  • Beta: 2.95
  • Short Ratio: 4.13
 

Frequently Asked Questions for Dimension Therapeutics (NASDAQ:DMTX)

What is Dimension Therapeutics' stock symbol?

Dimension Therapeutics trades on the NASDAQ under the ticker symbol "DMTX."

How were Dimension Therapeutics' earnings last quarter?

Dimension Therapeutics, Inc. (NASDAQ:DMTX) released its earnings results on Tuesday, August, 8th. The company reported ($0.49) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.49). The business had revenue of $4.37 million for the quarter. Dimension Therapeutics had a negative return on equity of 98.72% and a negative net margin of 358.21%. View Dimension Therapeutics' Earnings History.

Where is Dimension Therapeutics' stock going? Where will Dimension Therapeutics' stock price be in 2017?

6 brokerages have issued 1 year price targets for Dimension Therapeutics' stock. Their forecasts range from $3.00 to $7.00. On average, they anticipate Dimension Therapeutics' stock price to reach $5.08 in the next year. View Analyst Ratings for Dimension Therapeutics.

What are analysts saying about Dimension Therapeutics stock?

Here are some recent quotes from research analysts about Dimension Therapeutics stock:

  • 1. According to Zacks Investment Research, "Dimension Therapeutics, Inc. is a biotechnology company which focuses on developing novel, liver-directed gene therapy treatments for severe, rare genetic disorders. The company's pipeline of programs includes DTX101, a lead gene therapy product candidate designed to deliver Factor IX, gene expression for hemophilia B; DTX301, a gene therapy product candidate for the treatment of patients with ornithine transcarbamylase deficiency; DTX401, a gene therapy program for the treatment of patients with glycogen storage disease type Ia, a disease that arises from a defect in glucose-6-phosphatase and DTX201, a gene therapy program for the treatment of hemophilia A, which are in different clinical trial stage. Dimension Therapeutics, Inc. is based in Cambridge, Massachusetts. " (7/10/2017)
  • 2. Cantor Fitzgerald analysts commented, "We are lowering our rating to Neutral from Overweight and price target to $3 from $32, following initial results from Dimension's Phase 1/2 Study with DTX101 in Hemophilia B. Results highlighted that DTX101 will require additional optimization to be competitive with currently ongoing Hemophilia B gene therapy programs. While DTX101 was able to achieve meaningful peak FIX levels, these levels declined significantly in all patients. In addition, five of six patients demonstrated elevated levels of ALTs, which could hinder the company's ability to dose higher. Seeing the need for additional optimization for the hemophilia B program, we are moving to the sidelines and adjusting our price target." (1/31/2017)

Who are some of Dimension Therapeutics' key competitors?

Who are Dimension Therapeutics' key executives?

Dimension Therapeutics' management team includes the folowing people:

  • Georges Gemayel Ph.D., Chairman of the Board
  • Annalisa M. Jenkins, President, Chief Executive Officer, Director
  • Mary T. Thistle, Principal Financial and Accounting Officer, Chief Operating Officer
  • Samuel C. Wadsworth Ph.D., Chief Scientific Officer
  • Eric Crombez M.D., Chief Medical Officer
  • John Hohneker, Director
  • Alan B. Colowick M.D., Independent Director
  • Michael Dybbs Ph.D., Independent Director
  • George V. Migausky, Independent Director
  • Arlene M. Morris, Independent Director

How do I buy Dimension Therapeutics stock?

Shares of Dimension Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Dimension Therapeutics' stock price today?

One share of Dimension Therapeutics stock can currently be purchased for approximately $5.98.


MarketBeat Community Rating for Dimension Therapeutics (NASDAQ DMTX)
Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  122 (Vote Outperform)
Underperform Votes:  115 (Vote Underperform)
Total Votes:  237
MarketBeat's community ratings are surveys of what our community members think about Dimension Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Dimension Therapeutics (NASDAQ:DMTX) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 5 Hold Ratings, 1 Buy Rating
Consensus Rating:Hold (Score: 2.17)
Consensus Price Target: $5.08 (14.95% downside)
Consensus Price Target History for Dimension Therapeutics (NASDAQ:DMTX)
Price Target History for Dimension Therapeutics (NASDAQ:DMTX)
Analysts' Ratings History for Dimension Therapeutics (NASDAQ:DMTX)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
10/3/2017Wells Fargo & CompanyDowngradeOutperform -> Market Perform$9.00 -> $6.00LowView Rating Details
10/3/2017Citigroup Inc.UpgradeSell -> Neutral$5.50 -> $6.00MediumView Rating Details
8/30/2017Canaccord GenuityDowngradeBuy -> Hold$12.00 -> $3.41LowView Rating Details
8/14/2017Chardan CapitalReiterated RatingHoldLowView Rating Details
6/10/2017Cantor FitzgeraldSet Price TargetHold$3.00HighView Rating Details
2/2/2017Jefferies Group LLCReiterated RatingBuy$7.00N/AView Rating Details
3/30/2016Goldman Sachs Group, Inc. (The)DowngradeBuy -> Neutral$10.00N/AView Rating Details
11/6/2015Roth CapitalInitiated CoverageBuy$31.00N/AView Rating Details
(Data available from 10/19/2015 forward)

Earnings

Earnings History for Dimension Therapeutics (NASDAQ:DMTX)
Earnings by Quarter for Dimension Therapeutics (NASDAQ:DMTX)
Earnings History by Quarter for Dimension Therapeutics (NASDAQ DMTX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/8/2017Q2 2017($0.49)($0.49)$4.37 millionViewN/AView Earnings Details
5/10/2017Q1 2017($0.52)($0.54)$3.62 millionViewN/AView Earnings Details
3/9/2017Q4 2016($0.56)($0.53)$3.04 million$4.10 millionViewN/AView Earnings Details
11/10/2016Q3 2016($0.56)($0.58)$2.37 million$2.76 millionViewN/AView Earnings Details
8/11/2016Q2 2016($0.43)($0.49)$2.21 million$2.37 millionViewN/AView Earnings Details
5/12/2016Q116($0.57)($0.38)$2.24 million$2.21 millionViewN/AView Earnings Details
3/24/2016Q4 2015($0.38)($0.45)$1.70 million$2.35 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Dimension Therapeutics (NASDAQ:DMTX)
2017 EPS Consensus Estimate: ($2.18)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.53)($0.53)($0.53)
Q2 20171($0.54)($0.54)($0.54)
Q3 20171($0.55)($0.55)($0.55)
Q4 20171($0.56)($0.56)($0.56)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Dimension Therapeutics (NASDAQ:DMTX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Dimension Therapeutics (NASDAQ:DMTX)
Insider Ownership Percentage: 2.18%
Institutional Ownership Percentage: 70.33%
Insider Trades by Quarter for Dimension Therapeutics (NASDAQ:DMTX)
Institutional Ownership by Quarter for Dimension Therapeutics (NASDAQ:DMTX)
Insider Trades by Quarter for Dimension Therapeutics (NASDAQ:DMTX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
6/7/2016K. Reed ClarkSVPSell5,000$10.00$50,000.00View SEC Filing  
10/27/2015Rishi GuptaDirectorBuy200,000$13.00$2,600,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Dimension Therapeutics (NASDAQ:DMTX)
Latest Headlines for Dimension Therapeutics (NASDAQ:DMTX)
Source:
DateHeadline
finance.yahoo.com logoWEISSLAW LLP: Dimension Therapeutics, Inc. Acquisition May Not Be in the Best Interests of DMTX Shareholders
finance.yahoo.com - October 13 at 6:31 PM
finance.yahoo.com logoSHAREHOLDER UPDATE: Brodsky & Smith, LLC Announces an Investigation of Dimension Therapeutics, Inc. - DMTX
finance.yahoo.com - October 13 at 6:31 PM
americanbankingnews.com logoDimension Therapeutics, Inc. (DMTX) Receives Average Recommendation of "Hold" from Analysts
www.americanbankingnews.com - October 11 at 8:49 AM
finance.yahoo.com logoHarwood Feffer LLP Announces Investigation of Dimension Therapeutics, Inc.
finance.yahoo.com - October 5 at 5:08 PM
prnewswire.com logoDimension (DMTX) Alert: Johnson Fistel Investigates Proposed Sale of Dimension Therapeutics, Inc.; Are Shareholders Getting a Fair Price?
www.prnewswire.com - October 3 at 5:50 PM
finance.yahoo.com logo​After bidding war, North Bay drug maker snags gene therapy company for $151 million
finance.yahoo.com - October 3 at 5:50 PM
americanbankingnews.com logoDimension Therapeutics, Inc. (DMTX) Downgraded to Market Perform at Wells Fargo & Company
www.americanbankingnews.com - October 3 at 4:40 PM
rttnews.com logoVICL Soars After-hours, DMTX Deems RARE Bid Superior, MDXG On Watch
www.rttnews.com - October 3 at 8:49 AM
nasdaq.com logoUltragenyx To Acquire Dimension Therapeutics In Approx. $151 Mln Deal
www.nasdaq.com - October 3 at 8:49 AM
finance.yahoo.com logoUltragenyx to Acquire Dimension Therapeutics
finance.yahoo.com - October 3 at 8:49 AM
americanbankingnews.com logoDimension Therapeutics, Inc. (DMTX) Cut to Sell at Citigroup Inc.
www.americanbankingnews.com - September 24 at 1:00 PM
nasdaq.com logoDimension Board of Directors Determines Proposal from Ultragenyx ...
www.nasdaq.com - September 21 at 5:59 PM
finance.yahoo.com logoDimension Board of Directors Determines Proposal from Ultragenyx Pharmaceutical Inc. Could Reasonably Be Expected to Lead to a “Superior Proposal”
finance.yahoo.com - September 19 at 11:01 PM
rttnews.com logoUltragenyx Proposes To Buy Dimension Therapeutics For $5.50/shr In Cash
www.rttnews.com - September 19 at 1:24 AM
247wallst.com logoWill Dimension Therapeutics Take the New and Bigger Buyout Offer?
247wallst.com - September 19 at 1:24 AM
finance.yahoo.com logoUltragenyx Proposes to Acquire Dimension Therapeutics for $5.50 Per Share in Cash
finance.yahoo.com - September 18 at 3:20 PM
finance.yahoo.com logoUltragenyx Makes Bid for Dimension Therapeutics - Biotech Movers
finance.yahoo.com - September 18 at 3:20 PM
finance.yahoo.com logoUPDATED: Dimension Therapeutics shares surge 38% on Ultragenyx bid
finance.yahoo.com - September 18 at 3:20 PM
finance.yahoo.com logoDimension Confirms Receipt of Unsolicited Proposal from Ultragenyx
finance.yahoo.com - September 18 at 3:20 PM
americanbankingnews.com logoDimension Therapeutics, Inc. (DMTX) Given Consensus Recommendation of "Hold" by Analysts
www.americanbankingnews.com - September 16 at 9:10 AM
americanbankingnews.com logoDimension Therapeutics, Inc. (DMTX) Expected to Announce Earnings of -$0.49 Per Share
www.americanbankingnews.com - September 15 at 4:28 AM
americanbankingnews.com logoDimension Therapeutics (DMTX) & Madrigal Pharmaceuticals (MDGL) Critical Analysis
www.americanbankingnews.com - September 6 at 12:16 AM
finance.yahoo.com logoOncoSec Appoints Industry Veteran Annalisa Jenkins MBBS, FRCP to Board of Directors
finance.yahoo.com - September 5 at 7:29 PM
finance.yahoo.com logoETFs with exposure to Dimension Therapeutics, Inc. : August 31, 2017
finance.yahoo.com - August 31 at 10:12 PM
finance.yahoo.com logoSHAREHOLDER ALERT: Monteverde & Associates PC Announces An Investigation Of Dimension Therapeutics, Inc. - DMTX
finance.yahoo.com - August 31 at 10:12 PM
finance.yahoo.com logoDimension Therapeutics Commences Patient Dosing in Global, Multi-Center Phase 1/2 Clinical Trial of DTX301 in Ornithine Transcarbamylase (OTC) Deficiency
finance.yahoo.com - August 31 at 5:11 PM
finance.yahoo.com logoINVESTOR ALERT: Brower Piven Commences an Investigation into the Proposed Sale of Dimension Therapeutics, Inc. and Encourages Shareholders to Contact the Firm for Additional Information
finance.yahoo.com - August 31 at 5:11 PM
americanbankingnews.com logoCanaccord Genuity Reaffirms Hold Rating for Dimension Therapeutics, Inc. (DMTX)
www.americanbankingnews.com - August 30 at 10:42 AM
finance.yahoo.com logoSHAREHOLDER ALERT: Brodsky & Smith, LLC Announces an Investigation of Dimension Therapeutics, Inc. - DMTX
finance.yahoo.com - August 28 at 10:45 PM
finance.yahoo.com logoSHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Concerning Whether the Sale of Dimension Therapeutics, Inc. to REGENXBIO Inc. is Fair to Shareholders
finance.yahoo.com - August 26 at 12:32 AM
baystreet.ca logoRegenxbio Buying Dimension Therapeutics for $3.41 Per Share
www.baystreet.ca - August 25 at 7:28 PM
businesswire.com logoSHAREHOLDER ALERT: Brower Piven Commences an Investigation into the Proposed Sale of Dimension Therapeutics, Inc. and Encourages Investors to Contact the Firm for Additional ...
www.businesswire.com - August 25 at 7:28 PM
finance.yahoo.com logoDimension Therapeutics, Inc. :DMTX-US: Earnings Analysis: Q2, 2017 By the Numbers : August 25, 2017
finance.yahoo.com - August 25 at 7:28 PM
finance.yahoo.com logoRockville biotech buys Cambridge gene therapy firm for $86M
finance.yahoo.com - August 25 at 7:28 PM
finance.yahoo.com logoDIMENSION THERAPEUTICS, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation of Buyout
finance.yahoo.com - August 25 at 7:28 PM
finance.yahoo.com logoSHAREHOLDER ALERT: Brower Piven Commences an Investigation into the Proposed Sale of Dimension Therapeutics, Inc. and Encourages Investors to Contact the Firm for Additional Information
finance.yahoo.com - August 25 at 7:28 PM
finance.yahoo.com logoALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Dimension Therapeutics, Inc.
finance.yahoo.com - August 25 at 7:28 PM
americanbankingnews.com logoDimension Therapeutics, Inc. (DMTX) Given Consensus Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - August 22 at 9:08 AM
americanbankingnews.com logoDimension Therapeutics, Inc. (DMTX) Posts Quarterly Earnings Results, Hits Expectations
www.americanbankingnews.com - August 9 at 5:56 PM
finance.yahoo.com logoDimension Therapeutics Reports Second Quarter 2017 Financial Results and Provides Corporate Update
finance.yahoo.com - August 8 at 5:40 PM
finance.yahoo.com logoDimension Therapeutics reports 2Q loss
finance.yahoo.com - August 8 at 5:40 PM
americanbankingnews.com logoDimension Therapeutics, Inc. (NASDAQ:DMTX) Receives Consensus Rating of "Hold" from Brokerages
www.americanbankingnews.com - July 28 at 8:46 AM
finance.yahoo.com logoDimension Therapeutics Announces Management Change
finance.yahoo.com - July 24 at 10:33 AM
americanbankingnews.com logoDimension Therapeutics, Inc. (DMTX) Expected to Post Earnings of -$0.49 Per Share
www.americanbankingnews.com - July 20 at 9:15 AM
americanbankingnews.com logoAnalyzing Dimension Therapeutics (NASDAQ:DMTX) & vTv Therapeutics (VTVT)
www.americanbankingnews.com - July 18 at 6:10 PM
americanbankingnews.com logoDimension Therapeutics, Inc. (DMTX) Short Interest Update
www.americanbankingnews.com - July 16 at 7:06 AM
finance.yahoo.com logoWomen In Bio Announces Mary Thistle Joins Enterome’s Board of Directors
finance.yahoo.com - July 13 at 7:11 PM
finance.yahoo.com logoEnterome Appoints Mary Thistle to its Board of Directors
finance.yahoo.com - July 12 at 5:26 AM
americanbankingnews.com logoDimension Therapeutics, Inc. (DMTX) Given New $12.00 Price Target at Canaccord Genuity
www.americanbankingnews.com - July 3 at 11:58 PM
News IconBRIEF-Dimension Therapeutics reports Q1 loss per share $0.54
www.businessinsider.com - May 12 at 10:21 PM

Social

Chart

Dimension Therapeutics (DMTX) Chart for Thursday, October, 19, 2017

This page was last updated on 10/19/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.